Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHIELD: HyQvia for prevention of early infections in multiple myeloma
2023-505053-40-00Phase 2Completed
- Sponsor
- Sygehus Lillebælt
- Start
- Nov 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 2, randomised trial of Human normal immunoglobulin G in multiple myeloma (MM) (2 arms), sponsored by Sygehus Lillebælt. Primary endpoint: Annualized incidence of severe infections. Started Nov 2023; status: completed.
02
Drugs
Human normal immunoglobulin G
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-505053-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505053-40-00.